Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Targeted therapy in NSCLC at ASCO 2020

Riyaz Shah • 19 Jun 2020
ASCO 2020
Lung Cancer Non-Small Cell Lung Cancer Osimertinib
ADAURA

Riyaz Shah, FRCP, PhD, Maidstone and Tunbridge Wells NHS Trust, Kent, UK, gives his thoughts on the data coming from the ADAURA study (NCT02511106) and other targeted therapies in the treatment of non-small cell lung cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Riyaz Shah

3:17
Key insights from BTOG 2024: MARS 2 and HIT-MESO
Riyaz Shah • 18 Apr 2024
2:42
The benefits of immunotherapy versus chemotherapy: analyzing the results of the IPSOS trial
Riyaz Shah • 28 Apr 2023
2:35
CheckMate-816: what does the data tell us?
Riyaz Shah • 28 Apr 2023
2:49
SYSTEMS-2: radiotherapy in mesothelioma
Riyaz Shah • 28 Apr 2023

Related Videos

2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals